Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Neurocrine Biosciences
With that in mind, let's take a closer look at Neurocrine's business and see what CAPS investors are saying about the stock right now.
|Headquarters (Founded)||San Diego, Calif. (1992)|
|Market Cap||$522.6 million|
|Trailing-12-Month Revenue||$74.6 million|
|Management||CEO Kevin Gorman
CFO Timothy Coughlin
|Trailing-12-Month Return on Equity||36.8%|
|Cash/Debt||$177.5 million / $0|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 14% of the 360 members who have rated Neurocrine believe the stock will underperform the S&P 500 going forward.
Neurocrine has been turning in solid pipeline progress for several years now but they haven't had much success holding gains in the share price. Now that the phase III trial of [E]lagolix is in progress I expect at least a year before all 875 patients are enrolled and possibly another year before topline data is released. I'm not expecting any other catalysts in the near future and if previous patterns hold the share price will drift back below [$7] before the runup into phase III data.
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit From the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.